Showing results (251-260 of 446) with videos related to
Sort By:
Pageof 45
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|January 30, 2026
Sustainable kidney care: A life cycle assessment of the peritoneal dialysis pathwaysJames Larkin, Giulia Ligabue, Gaetano Alfano, et al.Exploratory Research in Clinical and Social Pharmacy|February 19, 2025
Out-of-pocket prescription medicine expenditure amongst community-dwelling adults: Findings from the Irish longitudinal study on ageing (TILDA) in 2016James Larkin, Ciaran Prendergast, Logan T Murry, et al.Cancer Treatment Reviews|September 27, 2025
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature reviewNatalie Charnley, Kate Fife, Daniel Y C Heng, et al.JAMA Oncology|August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical TrialsAxel Hauschild, James Larkin, Antoni Ribas, et al.Research in Social & Administrative Pharmacy : RSAP|May 28, 2025
Modelling the impact of changes to prescription medicine cost-sharing schemes among middle aged and older adultsJames Larkin, Ciaran Prendergast, Logan T Murry, et al.Investigational New Drugs|August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaSimon Pacey, Martin Gore, David Chao, et al.Journal of Nephrology|September 15, 2025
A life cycle assessment of peritoneal dialysis procurement in Italy: environmental burden and opportunities for improvementJames Larkin, Giulia Ligabue, Gaetano Alfano, et al.European Urology|November 6, 2016
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be AnsweredGrant D Stewart, Michael Aitchison, Axel Bex, et al.Journal of Translational Medicine|August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trialsPaolo A Ascierto, Antoni Ribas, James Larkin, et al.Nature Communications|July 8, 2026
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinomaVan To, Niko Thio, Rebecca Castle, et al.Pageof 45